Even if it does not look like the Author is crowning NGAL as the winner  as the “one-and-only-biomarker” for AKI:)

One of the reasons for this is the large variation on cut-off’s used… well – that we can  change easily – in a jiffy 🙂 … it’s just a matter of  Alere/abbott et al using the RIGHT cutoff-value (250 ng/ml)

Anyway – the most important point made in the Presentation is;  that in spite of 40 years of intense research,  researchers and scientists are still struggling to expand the “window of opportunity” for satisfactory treatment of AKI.. – Because – as we all know  Therapies will only work if the patient is diagnosed rapidly and correctly

Read the article on AKI here.

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.